A 38-year-old man from Kerala presents with a 4-month history of left-sided nasal obstruction, epistaxis, and left ear fullness. On examination, he has a left cervical mass (3 cm, hard, non-tender) and left conductive hearing loss with a dull tympanum. Nasal endoscopy shows a nasopharyngeal mass. Imaging reveals a 4 cm nasopharyngeal tumor with invasion of the left lateral pharyngeal wall and pterygoid fossa, bilateral cervical lymphadenopathy (largest node 5 cm on left, 4 cm on right), and no distant metastases. What is the most appropriate next step in management after staging?

Explanation

## Management of Locally Advanced Nasopharyngeal Carcinoma ### TNM Stage of This Patient - **Primary tumor (T):** 4 cm with invasion of lateral pharyngeal wall and pterygoid fossa = **T3** - **Regional nodes (N):** Bilateral cervical lymph nodes (largest ≤6 cm) = **N2** - **Distant metastasis (M):** None = **M0** - **Overall Stage:** T3N2M0 = **Stage III** (locally advanced, non-metastatic) ### Treatment Algorithm for Nasopharyngeal Carcinoma ```mermaid flowchart TD A[Nasopharyngeal Carcinoma]:::outcome --> B{Metastatic?}:::decision B -->|Yes, M1| C[Palliative chemotherapy]:::action B -->|No, M0| D{Locally advanced?}:::decision D -->|Early stage T1N0| E[Radiotherapy alone]:::action D -->|Locally advanced T2-T4 or N1-N3| F[Concurrent chemoradiotherapy CCRT]:::action F --> G[Cisplatin 40 mg/m² weekly during RT]:::action G --> H[Adjuvant chemotherapy if high-risk]:::action H --> I[Follow-up imaging at 8-12 weeks]:::outcome ``` ### Standard Treatment Regimens by Stage | Stage | Primary Treatment | Chemotherapy Role | |-------|-------------------|-------------------| | I (T1N0) | Radiotherapy alone | None | | II (T1N1 or T2N0-N1) | CCRT ± adjuvant CT | Concurrent cisplatin | | III–IVA (T3-T4 or N2-N3) | CCRT ± adjuvant CT | Concurrent + adjuvant cisplatin | | IVB (M1) | Palliative chemotherapy | Platinum-based regimen | **Key Point:** **Concurrent chemoradiotherapy (CCRT)** is the gold standard for locally advanced (Stage III–IVA) nasopharyngeal carcinoma. Cisplatin 40 mg/m² weekly during radiotherapy improves overall survival by ~10% compared to radiotherapy alone. **High-Yield:** Nasopharyngeal carcinoma is **radiosensitive** — radiotherapy is the cornerstone of treatment for all non-metastatic stages. The addition of concurrent chemotherapy (not neoadjuvant) improves locoregional control and survival in Stage III–IVA disease. **Clinical Pearl:** The **conductive hearing loss** (dull tympanum) is due to **Eustachian tube obstruction** from the nasopharyngeal mass — a classic presenting sign. This resolves with successful treatment of the primary tumor. ### Why NOT the Other Options - **Radical neck dissection first:** Neck dissection is NOT the primary treatment for nasopharyngeal carcinoma. Radiotherapy (with concurrent chemotherapy) treats both the primary and regional nodes. Neck dissection is reserved for residual or recurrent nodes after CCRT (salvage surgery). - **Neoadjuvant chemotherapy:** While some protocols use neoadjuvant CT for very advanced disease (T4 or N3), **concurrent chemoradiotherapy is the standard of care** for this patient's Stage III disease. Neoadjuvant CT may delay definitive radiotherapy and is not first-line. - **Palliative chemotherapy:** This patient has **no distant metastases** (M0) — he is a candidate for curative intent treatment with CCRT, not palliative care.